Background Euglycemic diabetic ketoacidosis (EDKA) is a potentially life-threatening
condition and a reported side effect of antidiabetic sodium-glucose-cotransporter-2 …

Introduction Glucose-lowering drugs pose a potential infection risk among individuals with
type 2 diabetes. The US Food and Drug Administration has issued safety warnings …

Objective We aimed to investigate the factors associated with UTI in patients with T2D
whether being treated with SGLT-2i or not. Methods Adult patients with T2D, whose urine …

Background: SGLT-2 inhibitors (SGLT-2is) are considered to be a first-line treatment for
common conditions like type 2 diabetes, chronic kidney disease, and heart failure due to …

Background International longitudinal studies have indicated an increasing incidence of
diabetic ketoacidosis (DKA). We aim to examine the incident trends, demographic …

Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are human antidiabetic drugs that are
increasingly used in equine practice for the management of hyperinsulinaemia and …

Treating type 2 diabetes (T2D) patients with sodium–glucose cotransporter 2 (SGLT2)
inhibitors may be associated with an increased risk of urinary tract infections (UTIs), such as …

Objective To analyze the frequency of new urologic visits and urologic diagnoses in patients
prescribed sodium-glucose co-transporter-2 inhibitors (SGLT-2is). Material and Methods …

Fournier's gangrene (FG) represents most urologists' least favorite consult. It is acute,
potentially lifethreatening (contemporary mortality rates between 5% and 10%), and often …

Sodium-glucose cotransporter 2 inhibitors are the latest medications to be approved and
released for treatment of patients with type 2 diabetes. These include canagliflozin …